Norovirus Vaccine Study

A Phase 3, Randomized, Observer-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Study Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age and Older

The study will involve a total of 7 visits to our clinic (located in Guelph, Ontario) and 6 remote phone calls over a 25 month period. Reasonable compensation is provided for time and efforts participating in the study.

Norovirus is the leading cause of acute gastroenteritis globally, marked by sudden nausea, vomiting, and diarrhea. Additional symptoms can include abdominal pain, headache, fatigue, and chills. You would receive the vaccine (mRNA-1403) or placebo as part of participation in the study. This study aims to evaluate the safety and efficacy of the investigational vaccine in preventing acute gastroenteritis caused by Norovirus.

You may be eligible if you:

Are 18 years of age or older

Are considered medically stable

DO NOT have chronic gastrointestinal conditions causing frequent vomiting or diarrhea

Have not had any changes to medications in the last 60 days

Norovirus Vaccine Study

Participation will include:

7 visits to our clinic (located in Guelph, ON) + 6 remote phone calls
Receiving the study product in the form of a vaccine
Blood draw at each visit
Daily eDiary completion for 7 days
Weekly eDiary completion for remainder of study

SEE IF YOU QUALIFY

How it works:

Facility Features

We take pride in our bright, modern clinic that we continue to upgrade to ensure a comfortable clinical trial experience for you. Click here to take a virtual tour of our space.